More representative trial populations and standardized subgroup reporting are needed in non–small cell lung cancer (NSCLC) research, according to a meta-analysis published in Cancers, which found no ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...

Exelixis, Inc. today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® versus placebo in patients with previously treated advanced neuroendocrine ...

EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free ...

We review Bayesian and Bayesian decision theoretic approaches to subgroup analysis and applications to subgroup-based adaptive clinical trial designs. Subgroup analysis refers to inference about ...

Introduction Many neonatal deaths are avoidable using existing low-cost evidence-based interventions. This study evaluated ...

Two new analyses of the FINEARTS-HF trial may help physicians decide how, and for whom, finerenone can best be used to treat heart failure with mildly reduced or preserved ejection fraction ...

Safety and feasibility of esophagectomy following neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: Analysis of two ...